newsfilter
← Latest News
Business Wire·

Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

-- Expected to accelerate clinical development pathway of CYB004 for the potential treatment of anxiety disorders by nine months -- Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psyc